Retinal Biologics Market Size, Share, And Growth Report 2032

Retinal Biologics Market: Size

The global Retinal Biologics Market size was worth around USD 24.79 billion in 2023 and is predicted to grow to around USD 49.56 billion by 2032 with a compound annual growth rate (CAGR) of roughly 8.00% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Retinal Biologics Market on a global and regional level.

Request Free Sample

Retinal Biologics Market: Overview

The retina is a sensitive and delicate part of the human eye, which receives and processes light and converts it into neural signals and forwards them to the brain for performing visual activities. Retinal disorders include macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis.

The worldwide escalation of ophthalmic disorders, due to aging, is the prime factor driving the retinal biologics market globally. The development of several new products in the form of drug-releasing implants and biologics due to the consistent efforts for developing better treatment options are further propelling the market for retinal biologics. The developments in the biologics in the field of ophthalmology have completely changed the way patients are treated in the current times. However, the limited availability of the biologics, adverse effects of biologics, strict regulatory requirements associated with biologics approval, and the lack of accessibility for biologics and effective drugs due to the high prices may hamper the market for retinal biologics in the future.

Request Free Sample

Retinal Biologics Market: Segmentation

The study provides a decisive view of the global retinal biologics market is segmented based on drug class, indication, distribution channel, and region.

By drug class, the market includes TNF-α inhibitor and VEGF-An antagonist.

On the basis of indication, the retinal biologics market comprises diabetic macular edema, macular degeneration, diabetic retinopathy, uveitis, and others.

The distribution channel segment includes retail sales and institutional sales. The retail sales segment includes mail order and retail pharmacies. The institutional sales segment is bifurcated into specialty clinics and hospitals. The institutional sales segment accounted for the largest share in the retinal biologics market in 2023.

Retinal Biologics Market: Report Scope

Retinal Biologics Market: Regional Analysis

The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

In Europe, rising incidences retinal disorders is fuelling the regional retinal biologics demand. This, in turn, is supporting the region’s retinal biologics market. The cases of retinal diseases in the Asia Pacific region were less as compared to other regions. However, this figure is likely to increase in the upcoming years, which will support the region’s retinal biologics market. Diabetes plays a significant role in retinal disease treatment. The rising rate of diabetes in the developing nations, due to unhealthy habits and inactive lifestyle, will also boost the retinal biologics market in the region.

Retinal Biologics Market: Competitive Players

Some key players of the retinal biologics market are:

• Janssen Biotech
• Alimera Sciences
• F. Hoffmann-La Roche
• Ocular Therapeutix
• Genzyme Corporation
• UCBCares
• AbbVie
• Allergan
• Swedish Orphan Biovitrum
• Genentech
• Bristol-Myers Squibb
• Bausch & Lomb.

The Global Retinal Biologics Market is segmented as follows:

Global Retinal Biologics Market: Drug Class Analysis

• TNF-α Inhibitor
• VEGF-A Antagonist

Global Retinal Biologics Market: Indication Analysis

• Diabetic Retinopathy
• Macular Degeneration
• Uveitis
• Diabetic Macular Edema
• Others

Global Retinal Biologics Market: Distribution Channel Analysis

• Retail Sales
  • Mail Order Pharmacies
  • Retail Pharmacies
• Institutional Sales
  • Hospitals
  • Specialty Clinics

Global Retinal Biologics Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa